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Abstract. 
 
Leukocyte antigen–related protein (LAR) is 
a prototype for a family of transmembrane protein ty-
rosine phosphatases whose extracellular domain is 
composed of three Ig and several fibronectin type III 
(FnIII) domains. Complex alternative splicing of the 
LAR-FnIII domains 4–8 has been observed. The extra-
cellular matrix laminin–nidogen complex was identified 
as a ligand for the LAR-FnIII domain 5 (Fn5) using a 
series of GST-LAR-FnIII domain fusion proteins and 
testing them in in vitro ligand-binding assays. LAR–
laminin–nidogen binding was regulated by alternative 
splicing of a small exon within the LAR-Fn5 so that in-
clusion of this exon sequence resulted in disruption of 
the laminin–nidogen-binding activity. Long cellular 
processes were observed when HeLa cells were plated 
on laminin–nidogen, but not when plated on a fibronec-
tin surface. Indirect immunofluorescent antibody stain-
ing revealed high expression of LAR in a punctate pat-
tern, throughout the length of these cellular processes 
observed on laminin–nidogen. Antibody-induced cross-
linking of LAR inhibited formation of these cellular 
processes, and inhibition was correlated with changes in 
cellular actin cytoskeletal structure. Thus, LAR–lami-
nin–nidogen binding may play a role in regulating cell 
signaling induced by laminin–nidogen, resulting in cell 
morphological changes.
 
R
 
egulation
 
 of protein tyrosine phosphorylation is a
vital component of extracellular matrix (ECM)
 
1
 
–
induced signal transduction. Changes in the ty-
rosine phosphorylation status of specific proteins are
implicated in the cytoskeletal reorganization required for
dynamic regulation of focal adhesion sites in signal transduc-
tion at these sites, and in the transmission of guidance signals
in motile cells (2). Protein tyrosine phosphorylation is regu-
lated by both protein tyrosine kinases and protein tyrosine
phosphatases (PTPases; 12). Nevertheless, the role of
PTPases in ECM-induced signal transduction is not well un-
derstood. A number of studies have implicated PTPase activ-
ity in cell adhesion, cell spreading, neurite extension, disas-
sembly of focal adhesion sites, and in signal transduction at
the tips of neuronal growth cones (2, 9, 11). However, with
the exception of the transmembrane PTPase CD45, which
may regulate integrin-induced tyrosine phosphorylation in
neutrophils (1), the identity and role of the transmembrane
PTPase(s) involved have not been elucidated.
Leukocyte antigen–related protein (LAR) is a proto-
type for a family of transmembrane PTPases whose extra-
cellular regions are composed of a combination of three
Ig-like domains and several fibronectin-type III (FnIII)
domains (see Fig. 1; 35, 37). Other members of this family
include mammalian PTP
 
d
 
 and PTP
 
s
 
, 
 
Drosophila
 
 DLAR,
and chicken CRYP-
 
a
 
 (24, 33, 43). LAR family PTPases
are prime candidates for regulating ECM-induced signal
transduction for the following reasons: the extracellular
region of these PTPases has a close similarity with the neu-
ral cell adhesion molecule (N-CAM) family of cell-adhe-
sion molecules (35); furthermore, LAR is located at the
disassembly side of focal adhesion sites, and in cadherin-
mediated cell–cell adhesion sites (18, 31). Chicken CRYP-
 
a
 
is localized to the tips of neuronal growth cones, and
 
Drosophila
 
 homolog of human LAR (DLAR) plays a role
in neuronal pathfinding (17, 33). Phenotypes of LAR
knockout mice suggest that LAR may also play a role in
morphogenesis of the mammary gland in mice (30).
The LAR cytoplasmic domain is composed of two PTP-
ase domains, the second of which appears to be catalyti-
cally inactive (36). Physiological substrates for the LAR
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PTPase are unknown. The LAR cytoplasmic domain binds
to a coiled-coil protein LIP.1, which might link LAR to cy-
toskeletal structures (31). The LAR C-terminus also asso-
ciates with a multidomain protein called Trio, which con-
tains a protein kinase domain and two guanine nucleotide
exchange factor domains that are, respectively, specific to
Rac1 and RhoA (5). These observations indicate a poten-
tial role for LAR in cytoskeletal reorganization induced
by cell–ECM contact that is mediated by Rac and Rho-
like molecules (39).
A number of observations suggest that the extracellular
domain of LAR also has an important function. The LAR
extracellular domain is proteolytically cleaved and under-
goes controlled shedding (31, 34). Furthermore, the FnIII
domains are alternatively spliced in a tissue-specific and
developmentally regulated manner (25, 42). The entire re-
gion containing the FnIII domains 4–7 is alternatively
spliced out in PTP
 
s
 
 and PTP
 
d
 
 (24, 43). Although this form
of alternative splicing has not been seen in LAR, we have
previously demonstrated alternative splicing of the LAR
FnIII domains 6 and 7, and of LAR FnIII domain 4 (25).
We also reported the alternative splicing of a small exon
(exon 13) within the LAR FnIII domain 5. Inclusion of
exon 13 within FnIII domain 5 may have a particular func-
tion in neuronal tissue, since cells of neuronal origin ex-
press the highest amount of exon 13 containing mRNA. In
all other cell types tested, the LAR isoform in which exon
13 is spliced out is the predominant form (25). Further-
more, alternative splicing of exon 13 is regulated in neu-
ronal tissues during embryonic development (43). Perhaps
more importantly, the alternatively spliced exon 13 is con-
served among LAR-like PTPases (human LAR, rat LAR
and PTP
 
d
 
; 25, 28). These observations suggest that alter-
native expression of FnIII domains 4–7 may have a con-
served function.
To study the role of the LAR FnIII domains 4–7, we
constructed a series of GST-LAR FnIII domain fusion
proteins and tested them in in vitro ligand-binding assays.
Using this approach, the ECM laminin-nidogen complex
was identified as a ligand for the LAR FnIII domain 5.
The laminin–nidogen complex is a major component of
the ECM that modulates cell adhesion, cell migration,
neurite outgrowth, cell proliferation, and cell differentia-
tion (21). The ability of laminin–nidogen to modulate such
a wide range of events is related to its large size and multi-
domain structure that allows the interaction of laminin–
nidogen with a number of different ligands. We found that
alternative splicing of exon 13 within the LAR FnIII do-
main 5 regulated LAR–laminin-nidogen–binding activity.
Furthermore, antibody-induced cross-linking of LAR in
HeLa cells alters laminin-nidogen–induced cell morphology.
 
Materials and Methods
 
Cells
 
U373 MG (human glioblastoma) and HeLa (human epithelioid carci-
noma) cells were obtained from the American Type Culture Collection
(Rockville, MD). U373 MG were grown in Eagles media (GIBCO BRL,
Gaithersburg, MD) containing 10% FCS. HeLa cells were grown in DME
media (Bio-Whittaker, Walkersville, MD) containing 10% FCS and sup-
plemented with 2 mM glutamine. Cells were maintained at 37
 
8
 
C in a hu-
midified atmosphere with 10% CO
 
2
 
.
 
Buffers
 
PBS: 10 mM sodium phosphate buffer (pH 7.4), 150 mM NaCl. HBS
buffer: 10 mM Hepes (pH 7.4), 150 mM NaCl. SDS sample buffer: 0.125 M
Tris (pH 6.8), 10% SDS, 25% glycerol, 0.01% bromophenol blue. Detach-
ment buffer: 2 mM EDTA, PBS, 0.05% BSA. Wash media: serum-free
DME media supplemented with 0.05% heat-inactivated BSA and 10 mM
Hepes (pH 7.4). BSA was heat-inactivated at 80
 
8
 
C for 20 min.
 
Anti-LAR Monoclonal Antibodies
 
The anti-LAR monoclonal antibodies 75.3A, 11.1A, and 71.2E have been
previously described (34). The anti-LAR monoclonal antibody 75.11.16
was raised by a similar approach using a GST-LAR Fn5-protein as anti-
gen. The epitopes in the LAR extracellular domain recognized by these
antibodies are as follows: mAb 75.3A, LAR Ig domain 1, 2, or 3; mAb
11.1A, between FnIII domain 8 and the transmembrane segment; mAb
71.2E, FnIII domain 6 or 7; mAb 75.11.16, LAR FnIII domain 5.
 
Other Antibodies
 
The antilaminin mAbs used were: antihuman laminin 
 
b
 
1
 
 chain (clone I)
and antihuman laminin 
 
g
 
1
 
 chain (clone II) from GIBCO BRL; and antihu-
man laminin (LAM-89) from Sigma Chemical Co. (St. Louis, MO). Affin-
ity-purified rabbit polyclonal anti-Engelbreth-Holm-Swarm (EHS)-lami-
nin was also from Sigma Chemical Co., and rabbit polyclonal anti-mouse
laminin B1/B2 chain was from Upstate Biotechnology Inc. (Lake Placid,
NY). Anti-human 
 
b
 
2 microglobulin mAb MIG-B5 was from BioSource
International (Camarillo, CA). Affini-pure rabbit anti–mouse IgG was
from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).
Monoclonal anti-human integrin 
 
b
 
1, anti-human talin, and anti-human
vinculin antibodies were from Upstate Biotechnology Inc. HRP-conju-
gated rabbit anti–mouse IgG antibody and TRITC-conjugated goat anti–
mouse IgG
 
1 
 
were from Southern Biotechnology Associates Inc. (Birming-
ham, AL).
 
Laminin and ECM Proteins
 
The following preparations of ECM proteins were used: Matrigel™ (base-
ment membrane matrix from the mouse EHS sarcoma; Becton Dickinson,
Bedford, MA); purified laminin–nidogen complex from the EHS sarcoma,
and human fibronectin (Boehringer Mannheim, Indianapolis, IN).
 
GST–LAR–FnIII Fusion Proteins
 
Fusion proteins of glutathione S-transferase (GST) with various LAR
FnIII domains were constructed using the 
 
E. coli
 
 expression vector
pGEX-2T (Pharmacia Biotech. Inc., Piscataway, NJ; 32). The GST-fusion
proteins used in this study are shown schematically in Fig. 1. Various seg-
ments of LAR cDNA with appropriate restriction sites for subcloning
were generated by PCR and inserted in-frame into the pGEX-2T vector
downstream of the GST coding sequence. Their nucleotide sequences
were confirmed by DNA sequencing. Fusion protein synthesis was in-
duced in exponentially growing 
 
Escherichia coli
 
 cultures by adding 0.1
mM isopropylthiogalactoside, and continued for 2 h at 25
 
8
 
C. Fusion pro-
teins were extracted by solubilizing the bacterial pellet with 1% Triton
X-100/PBS, containing 1.0 mM PMSF and 1.0 mM benzamidine for 30 min
at room temperature, followed by sonication for 30 s at 4
 
8
 
C. Fusion pro-
teins were affinity-purified using glutathione Sepharose beads. Beads were
washed five times with PBS. The purity and sizes of the fusion proteins
were confirmed by SDS-PAGE followed by Coomassie blue staining.
 
35
 
S-Labeling of Conditioned Media
 
U373 MG cells were grown to 80% confluency in 100-mm tissue culture
dishes in Eagle’s media containing 10% FCS. Cells were then washed
twice with serum-free media and metabolically labeled with [
 
35
 
S]methio-
nine/cysteine (Dupont-NEN, Boston, MA). In brief, cells were incubated
for 20 h in methionine-free media supplemented with [
 
35
 
S]methionine/cys-
teine (80 
 
m
 
Ci/ml), 5% dialyzed FCS (1,000 D cut-off), and 10 mM Hepes
buffer (pH 7.4). Labeled media was collected at 4
 
8
 
C, the protease inhibi-
tors (1.0 mM PMSF and 1.0 mM benzamidine) were added, and the media
was centrifuged at 1,500 rpm in a Beckman J-6M/E centrifuge at 4
 
8
 
C. 
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Ligand-binding Assays
 
The different GST-LAR-fusion proteins (20 
 
m
 
g) bound to glutathione
Sepharose beads were incubated with [
 
35
 
S]methionine-labeled media (5 ml)
collected from U373 MG cells. Incubation was carried out for 2 h at 4
 
8
 
C
with rotation. The incubation was terminated by centrifuging the beads at
1,000 rpm in a Beckman J-6M/E centrifuge for 5 min at 4
 
8
 
C. The beads
were washed four times with 5 ml of ice-cold HBS buffer. After the fourth
wash, the beads were resuspended in SDS sample buffer, reduced with
 
b
 
-mercaptoethanol, boiled, and subjected to SDS-PAGE on a 5% gel. A
sample of the media without incubation with the fusion proteins was run
on the gel to assess the number and relative concentration of the labeled
bands in the media. Gels were processed for autoradiography with En-
hance™ (Dupont-NEN) according to the manufacturer’s instructions.
Dried gels were exposed to x-ray film in the presence of an enhancer
screen.
Binding of GST-LAR Fn5 (with or without the exon 13 sequence) to
Matrigel™ was assayed as follows. Glutathione bead–bound GST-LAR
Fn5
 
1
 
 or Fn5
 
2
 
 (20-
 
m
 
l beads coated with 40 
 
m
 
g protein) was diluted into 10
ml HBS containing 2 mM EDTA, 1.0 mM PMSF, and 1.0 mM benzami-
dine, and mixed with various amount of Matrigel (150–750 
 
m
 
g) for 2 h at
4
 
8
 
C with rotation. The beads were then precipitated by centrifugation and
washed four times with 5 ml of ice-cold HBS buffer each. After the final
centrifugation, the beads were resuspended in SDS sample buffer, re-
duced with 
 
b
 
-mercaptoethanol, boiled, and subjected to SDS-PAGE on a
6.5% gel and immunoblotting. Blots were probed with the rabbit poly-
clonal anti-mouse laminin B1/B2 chain antibody, followed by HRP-conju-
gated goat anti–rabbit antibody. Bound antibodies were visualized by the
enhanced chemiluminescence reagent (Amersham Life Science Inc., Ar-
lington Heights, IL).
Binding of GST-LAR Fn5 proteins to the purified laminin-nidogen
complex was assayed in a similar manner, except that the concentration
of laminin-nidogen was kept constant (150 
 
m
 
g in 10 ml), while the amount
of GST-LAR Fn5 protein bound to glutathione beads varied (50–150 
 
m
 
g of
protein per 40 
 
m
 
l beads), and the mixtures were incubated for 3.5 h at 4
 
8
 
C
with rotation. Samples were analyzed on a 5% SDS gel, and blots were
probed with an affinity-purified polyclonal anti-laminin antibody.
 
Immunoblotting with Antilaminin Antibodies
 
Conditioned media collected from U373 MG cells was incubated with the
GST-LAR fusion proteins as described in the binding assay above. Elec-
trophoresis was carried out on a 3–12% gradient SDS-polyacrylamide gel
under nonreducing conditions, or on a 5% SDS-polyacrylamide gel under
reducing conditions. After electrophoresis, the gels were blotted to nitro-
cellulose and probed with monoclonal antibodies specific to the laminin 
 
b
 
1
 
chain, laminin 
 
g
 
1
 
 chain, or laminin (LAM-89). Bound anti-laminin anti-
bodies were detected with HRP-conjugated rabbit anti–mouse IgG anti-
bodies and the enhanced chemiluminescence reagent. Purified laminin-1
was run in parallel in all the gels as a positive control.
 
LAR Cross-linking
 
HeLa cells at 30–50% confluency were detached by incubation in detach-
ment buffer for 20 min at 37
 
8
 
C. Cells were washed three times at 4
 
8
 
C in
wash media. Cells were resuspended in wash media at a concentration of
0.4 
 
3 
 
10
 
6
 
 cells/ml, and 0.12 
 
3 
 
10
 
6 
 
cells were plated per well on laminin–
nidogen-coated 24-well tissue culture plates. Laminin–nidogen (Boeh-
ringer Mannheim) was coated at a concentration of 20 
 
m
 
g/ml PBS over-
night at 4
 
8
 
C. Before plating the cells, the laminin–nidogen-coated wells were
blocked for 1 h at room temperature by incubation with 0.5% heat-inacti-
vated BSA, and were then washed once with PBS. Cells were incubated
for 1 h at 37
 
8
 
C to allow the cells to attach and begin to spread. Unattached
cells were removed by washing with wash media at room temperature.
The cells were then incubated with the anti-LAR mAb 75.3A, 75.11.16, or
a control anti-human 
 
b
 
2 microglobulin mAb, at a concentration of 20 
 
m
 
g/ml
in wash media for 10 min at 37
 
8
 
C. A further control was the omission of a
first antibody. The media containing the unbound antibodies was re-
moved, and the bound antibodies were cross-linked with 60 
 
m
 
g/ml Affini-
pure™ rabbit anti–mouse IgG. Incubation at 37
 
8
 
C was continued for a fur-
ther 35 min. The cells were washed three times with PBS and fixed in
3.7% paraformaldehyde/PBS for 10 min at room temperature. The cells
were washed four times with PBS and photographed by phase contrast mi-
croscopy on a Axiovert 135 microscope (Carl Zeiss Inc., Thornwood, NY)
using Tri-X400 film (Eastman Kodak Co., Rochester, NY). Fractions of
spread cells were quantified by counting at least four random fields for
each of four separate experiments.
 
Immunofluorescent Microscopy
 
The laminin–nidogen complex (20 
 
m
 
g/ml) was coated overnight at 4
 
8
 
C
onto sterile, acid-washed 12-mm glass coverslips (Fisher Scientific Co.,
Pittsburgh, PA) in 24-well dishes (Costar Corp., Cambridge, MA). HeLa
cells were plated on the laminin–nidogen-coated coverslips, and were
treated as described for the cross-linking assay above. Cell surface LAR
was stained by a modification of the method of Serra-Pagès et al
 
.
 
 (31). In
brief, before LAR staining cells were fixed in 3.7% paraformaldehyde
(Fisher Scientific Co.) in PBS for 10 min. Fixation was required before
LAR staining in order to preserve the laminin–nidogen-induced cell mor-
phology. For staining internalized LAR and other intracellular proteins
(talin, vinculin, and actin), the cells were permeabilized with 0.4% Triton
X-100 in PBS for 5 min after fixation. After four washes with PBS, non-
specific binding sites were blocked with 10% goat serum in PBS (for
LAR, talin, and vinculin stainings) or 1% BSA in PBS (for actin staining)
for 30 min. LAR, talin, and vinculin were stained for 1 h with monoclonal
anti-LAR (11.1A), anti-talin, and anti-vinculin antibodies (10 
 
m
 
g/ml), re-
spectively, in PBS with 2% goat serum. After four washes with PBS, the
bound antibodies were detected by incubation for 1 h with TRITC-conju-
gated goat anti–mouse IgG
 
1
 
 (at 1:100 dilution) in PBS with 2% goat se-
rum. Actin was visualized by incubation of the cells with 2U rhodamine-
conjugated phalloidin (Molecular Probes Inc., Eugene, OR) in blocking
solution for 30 min according to the manufacturer’s instructions. For all
stainings, the specificity of staining was determined in control experiments
in which either the primary antibody or both the primary and secondary
antibodies were omitted.
After labeling, all slides were washed three times with PBS and
mounted in Fluorsave (Calbiochem-Novabiochem Corp., La Jolla, CA).
Slides were viewed on an Axiophot™ microscope (Carl Zeiss Inc.)
equipped for epifluorescence. Photographs were taken on Tri-X400 black
and white film (Eastman Kodak Co.).
 
Results
 
Ligand Binding of GST–LAR–FnIII Domain
Fusion Proteins
 
The complex alternative splicing of FnIII domains 4–7
among LAR family members suggests that these domains
may have an important function. One possibility is that
this region of LAR encodes a ligand-binding site. To test
this possibility, a series of GST fusion proteins containing
various LAR-FnIII domains were constructed for testing
in ligand-binding assays. The GST–LAR–FnIII constructs
used in this study are shown schematically in Fig. 1 
 
b
 
. Most
of the constructs that include the LAR-FnIII domain 5
were made in two different versions: with or without the
alternatively spliced exon 13, which encodes nine amino
acids. These versions are referred to as Fn5
 
1
 
 and Fn5
 
2
 
forms, respectively, throughout the text.
Initially we tested binding of the GST–LAR–FnIII fu-
sion proteins to components of the conditioned media
from cultured cells. Conditioned media is a potential
source of ligands such as ECM proteins. Incubation of 20 
 
m
 
g
GST–LAR–FnIII fusion proteins with [
 
35
 
S]methionine-
labeled conditioned media from U373 MG (human glio-
blastoma) cells revealed specific binding of 
 
z
 
350-, 220-,
and 
 
z
 
200-kD proteins to the GST-fusion constructs #3, #5,
#7,  and #8 (encoding Fn5
 
2
 
; Fn5
 
2
 
, 6, 7, 8; Fn3,4,5
 
2
 
; and
Fn5
 
2
 
, 8, respectively; Fig. 2). The bound proteins are
highly enriched by the LAR constructs when compared
with their concentration in the original media. Specificity
of binding is indicated by the observation that the ligand-
binding constructs all contained the Fn5- domain. All of 
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the Fn5
 
1
 
-containing isoforms showed only background
binding similar to the GST protein alone. The Fn5
 
2
 
 iso-
form bound the same three labeled bands whether the
Fn5
 
2
 
 domain was present as a single domain (construct
#3), or was flanked by other FnIII domains (constructs #5,
#7, and #8). The binding was also independent of the dis-
tance from the Fn5
 
2
 
 domain to the GST protein, indicat-
ing that the presence of the GST domain did not influence
binding. Construct 8, in which Fn5
 
2
 
 is joined directly to
Fn8, shows a weaker binding than the other Fn5
 
2
 
 con-
structs, suggesting that the presence of Fn6 and Fn7 may
influence the ligand-binding activity of Fn5
 
2
 
. Fn4 or Fn6
alone do not show specific ligand binding (constructs #9
and #10). Thus, the Fn5
 
2
 
 domain has a specific ligand-
binding capacity, while inserting nine amino acids in this
domain completely abolishes ligand binding.
 
The LAR-binding Protein Contains Laminin-1
 
The molecular masses of the Fn5
 
2
 
-binding proteins are
similar to those of the ECM protein laminin-1. Laminin-1
is a disulfide-bonded heterotrimer of 
 
z
 
350-, 220-, and
 
z
 
200-kD subunits (
 
a
 
1
 
, 
 
b
 
1
 
, and 
 
g
 
1
 
 chains, respectively), and
is reported to be synthesized and secreted into the media
by U373 MG cells (19). Indeed, laminin chains immuno-
precipitated from 
 
35
 
S-labeled media of U373 MG cells mi-
grated at the same positions as the Fn5- binding proteins
(data not shown). We therefore tested if the Fn5
 
2
 
-binding
protein is laminin by determining its reactivity to anti-
laminin antibodies.
First, the Fn5
 
1
 
 and Fn5
 
2
 
 isoforms (constructs #2 and
#3) were incubated with unlabeled conditioned media
from U373 MG cells, and the bound proteins were sepa-
rated by SDS-PAGE under nonreducing conditions fol-
lowed by immunoblotting. Under nonreducing conditions,
the laminin-1 trimer migrates as a protein of 
 
z
 
850 kD.
When probed with an antilaminin antibody, a high–molec-
ular weight protein was detected bound to the Fn5
 
2
 
, but
not to the Fn5
 
1
 
 isoform. This protein migrated at the
same molecular weight as the purified laminin-1, which
was run in parallel (Fig. 3 
 
a
 
). Next, the reactivity of anti-
bodies specific to the laminin-
 
b
 
1
 
 and -
 
g
 
1
 
 chains with the
Fn5
 
2
 
-bound ligands was tested in a similar assay, except
that electrophoresis was carried out under reducing condi-
tions. The anti-
 
b
 
1
 
 and anti-
 
g
 
1 laminin antibodies detected
bands of z220 kD and z200 kD, respectively, in the pro-
teins bound to the Fn52, but not to the Fn51, isoform.
These bands migrated at the same position as the laminin-
b1 and -g1 chains in purified laminin run in parallel (Fig. 3, b
and c).
Thus, laminin is specifically bound to the Fn52 fusion
Figure 1. Schematic outline of GST-LAR-FnIII domain fusion
proteins. The GST-LAR-fusion proteins constructed in the
pGEX plasmid are shown (b). The numbered boxes represent the
LAR-FnIII domains, and their position in the full-length LAR
molecule is shown at the top (a). The presence or absence of the
alternatively spliced exon in LAR-FnIII domain 5 is indicated by
a 1 or 2 sign, respectively.
Figure 2. Ligand binding of GST-LAR-FnIII domain fusion pro-
teins. The GST-LAR-FnIII domain fusion proteins, bound to
glutathione beads, were incubated with [35S]methionine-labeled
conditioned media from U373 MG cells. The incubation was ter-
minated by precipitation of the beads and associated proteins.
After extensive washing, bound proteins were analyzed by 5%
SDS-PAGE and autoradiography. The labeled bands of z350,
220, and 200 kD, which are specifically bound only by constructs
encoding the LAR-FnIII domain 5-, are indicated by arrows. An
aliquot of the labeled media, before incubation with the fusion
proteins, is shown on the right (Media). Constructs are numbered
as described in Fig. 1 b, and the presence of the 51 or 52 domain
is indicated at bottom.O’Grady et al. Laminin Complex Binds Transmembrane PTPase LAR 1679
protein. However, it cannot be concluded from these ex-
periments alone whether laminin is bound directly to
LAR, or indirectly via a molecule present in the condi-
tioned media that acts as a bridge between laminin and
LAR. Laminin-1 is generally found in a very tight 1:1 com-
plex with the extracellular matrix protein nidogen (also
known as entactin; 6, 40). The laminin–nidogen complex
has binding sites for a number of different ligands, includ-
ing collagen, perlecan, fibulin-1, heparin sulfate, and other
ECM components (3, 27, 40). To examine if the Fn52 do-
main binds the laminin–nidogen complex directly or not,
the Fn52 and 51 isoforms were incubated with either
Matrigel™ or the purified mouse laminin–nidogen com-
plex. Matrigel™ is a preparation of ECM from the mouse
EHS sarcoma, which is highly enriched for the laminin–
nidogen complex (15). Incubation of the Fn52 and Fn51
isoforms with increasing concentrations of Matrigel,™ fol-
lowed by immunoblotting with an anti-laminin antibody,
indicated a corresponding increase in binding of laminin to
the Fn52, but not the 51 isoform (Fig. 4 a). In another ex-
periment, the purified laminin–nidogen complex (constant
amount) was incubated with increasing amounts of the
Fn52 and Fn51 proteins. The purified laminin–nidogen
complex can also bind Fn52 in a dose-dependent manner,
suggesting that LAR binding to the laminin–nidogen com-
plex does not require any other ECM component (Fig. 4
b). At high concentrations of the Fn51 protein, some
laminin–nidogen binding is detected, suggesting that the
Fn51 may retain low-affinity binding to the laminin–
nidogen complex. These data therefore indicate that the
laminin–nidogen complex is a ligand for the LAR–Fn52
domain, although we cannot specify the exact binding
site(s) on the laminin–nidogen complex.
Role of LAR–Laminin–Nidogen Binding in
Cell Morphology
The above finding suggests a role for LAR in laminin–
nidogen–mediated cellular events. Laminin–nidogen bind-
Figure 3. Immunoblotting analysis of the GST–LAR–Fn52-
binding protein with anti-laminin antibodies. The identity of the
GST-LAR-Fn52 ligand was tested by immunoblotting with anti-
laminin antibodies. (a) GST-LAR-Fn52-bound proteins were
analyzed under nonreducing conditions on a 3–12% gradient
SDS-polyacrylamide gel. Probing with the anti-laminin antibody
recognizes a high molecular weight protein bound only by the
GST-LAR-Fn52 (52), but not by the GST–LAR–Fn51 isoform
(51; arrow at right). This GST-LAR-Fn52- bound protein mi-
grates at the same molecular weight as the purified laminin-1 tri-
mer shown in lane 1. (b) and (c) GST-LAR-Fn52- bound pro-
teins were analyzed under reducing conditions, which dissociate
laminin-1 into its constituent a1, b1, and g1 chains. Blots were
probed with the anti-laminin b1 (b) or the anti-laminin g1 (c) anti-
bodies. These antibodies detected proteins of z220 and 200 kD,
respectively, which were bound by the GST-LAR-Fn52, but not
by the 51 isoform (arrows). These bands migrated at an identical
position to the b1 and g1 chains in purified laminin-1 run in paral-
lel (laminin).
Figure 4. The laminin–nidogen complex directly binds the GST–
LAR–FnIII domain 5- isoform in a dose-dependent manner. (a)
The GST–LAR–Fn52 and Fn51 isoforms (40 mg protein) bound
to 20-ml glutathione beads were incubated with increasing con-
centrations of Matrigel™ (15–75 mg/ml in buffer; 10 ml total vol-
ume). Bead-bound proteins were analyzed by 6.5% SDS-PAGE
and immunoblotting with a polyclonal anti-laminin b1/g1 chain an-
tibody. (b) Increasing amounts of the GST–LAR–Fn52 and
Fn51 isoforms (50–150 mg protein) bound to 40 ml glutathione
beads were incubated with the purified laminin–nidogen complex
(15 mg/ml in buffer; 10 ml total volume). After extensive washing,
bead-bound proteins were analyzed by 5% SDS-PAGE and im-
munoblotting with a polyclonal anti-laminin antibody. Positions
of laminin subunits are indicated by arrows.The Journal of Cell Biology, Volume 141, 1998 1680
ing to cells modulates a number of cellular activities, in-
cluding cell differentiation, cell proliferation, cell adhesion,
and cell motility (6, 21, 40). The localization of LAR to the
disassembly side of focal adhesions suggests a role for
LAR in regulation of focal adhesions (31). Since focal ad-
hesions are sites of cell–ECM interaction and ECM-
induced signal transduction, LAR could potentially regu-
late laminin–nidogen–mediated cell adhesion and motility.
The HeLa (human epithelioid carcinoma) cell line was
chosen as a model system in which to investigate the func-
tional role of laminin–LAR interaction, because HeLa
cells express high amounts of the LAR protein that is pre-
dominantly the Fn5- isoform (25, 34). HeLa cells also ex-
hibit a distinct morphology when plated on a laminin–
nidogen substrate. After initial attachment and spreading
on laminin–nidogen, long, thin cellular processes are ex-
tended from HeLa cells (Fig. 5 a). 95 min after plating,
42% of the spreading cells already exhibit long processes
(Table I). These process are not observed when HeLa cells
are attached to fibronectin (Fig. 5 b) or to the nonspecific
attachment factor polylysine (data not shown). LAR
cross-linking experiments were carried out to determine if
LAR plays a role in the cell morphology induced by lami-
nin–nidogen in HeLa cells. Antibody-induced cross-link-
ing of LAR results in its aggregation on the cell surface,
and ultimately its internalization (31; also see Fig. 6).
Cross-linking of LAR in HeLa cells plated on a laminin–
nidogen substrate caused a dramatic change in the mor-
phology of the spreading cells. In LAR cross-linked cells,
formation of the laminin–nidogen-induced cellular pro-
cesses is inhibited by 97%, although the cells do remain at-
tached to the substrate (Table I; compare Fig. 5 a with Fig.
5, c and d). Similar inhibition of the cellular processes was
observed using four different anti-LAR mAbs with dis-
tinct epitopes in the LAR extracellular domain (data not
shown). Neither treatment of the cells with secondary anti-
body alone or a control cross-linking using anti-b2 micro-
globulin antibody affected the laminin–nidogen-induced cell
morphology (Fig. 5, e and f, respectively). HeLa cells ex-
press surface b2 microglobulin (26), which has been shown
to be sequestered after antibody-induced cross-linking (8).
Antibody-induced LAR cross-linking has been shown to
induce patching and ultimately internalization of cell sur-
face LAR (31). The extent of LAR internalization induced
by cross-linking over the time period of our study was de-
termined by immunofluorescence. Before LAR cross-link-
ing, (after plating on laminin–nidogen for 1 h), a high con-
centration of cell surface LAR was visualized (Fig. 6 a.).
After antibody-induced LAR cross-linking, however, cell
surface LAR was barely detectable (Fig. 6 b). Permeabili-
zation of the cross-linked cells followed by LAR staining
revealed high concentrations of aggregated LAR within
the cell, indicating internalization of LAR had occurred
after cross-linking (Fig. 6 c). As a control, we examined lo-
calization of the integrin b1 subunit after LAR cross-link-
ing. The integrin b1 subunit is a component of a number of
integrin cell surface laminin receptors (a1b1, a2b1, a3b1,
a6b1, and a7b1). There were no significant changes in the
distribution of the integrin b1 subunit (data not shown), in-
dicating that LAR cross-linking probably does not alter
cell morphology through cointernalization of integrin
laminin receptors.
Formation of cellular processes on laminin requires dy-
namic cytoskeletal reorganization. Actin staining of cells 1 h
after plating on a laminin–nidogen substrate indicates a
relatively disordered, meshwork actin cytoskeleton typical
of spreading cells (Fig. 7 a). As the cell extends long pro-
cesses, the actin skeleton becomes more organized, and a
long, thick actin fiber is seen to extend from the cell body
along the length of these processes (Fig. 7 b). This thick
central actin fiber is absent from the LAR cross-linked
cells where actin is present mainly as numerous thin stress
fibers (Fig. 7, c and d). Thus, correlating with the effect on
cell morphology, LAR cross-linking also affected the cel-
lular cytoskeletal structure.
Migration of cellular processes along an ECM requires
Figure 5. Effect of LAR cross-linking on HeLa cell morphology.
HeLa cells were detached with EDTA and plated under serum-
free conditions on the plates coated with the laminin–nidogen
complex (a, c–f) or fibronectin (b) for 1 h at 378C. LAR was then
cross-linked by incubation for 10 min at 378C with the anti-LAR
mAbs 75.3A (c) or 75.11.16 (d), followed by a 35-min incubation
with a rabbit anti–mouse IgG antibody. Controls in which HeLa
cells were treated with no antibody (a); with the second antibody
alone (e); or cross-linked with anti-b2 microglobulin antibody (f)
are also shown. Cells were then fixed with 3.7% paraformalde-
hyde for 10 min at room temperature, and washed in PBS. The
morphology of the cells was analyzed by phase contrast micros-
copy.
Table I. Effect of LAR Cross-linking on HeLa Cell Morphology
Cross-linking antibody
Fraction of spread cells
with one or more long processes (%)
Expt. 1 Expt. 2 Expt. 3 Expt. 4
None 41.6% 41.9% 41.8% 41.3%
(331/795) (131/313) (76/182) (57/138)
Anti-LAR (75.3A) 3.3% 3.4% 2.6% 2.5%
(21/630) (6/176) (5/190) (2/81)
Anti-b2 microglobulin 41.7% 36.7% 53.8%
(78/187) (40/109) (63/117)
HeLa cells (1.2 3 105 cells/well) were plated on the laminin–nidogen complex. Anti-
body-induced cross-linking, cell fixation, and phase contrast microscopy were carried
out as described in Fig. 5. In each experiment, fractions of spread cells with long ex-
tensions were quantified by counting cells from at least four randomly chosen fields.
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continuous assembly and disassembly of focal adhesions in
order to provide traction during migration (13). Localiza-
tion of LAR to the disassembly side of focal adhesions
(31) suggests a mechanism by which LAR might influence
the laminin-induced morphological changes in HeLa cells.
To determine if LAR is localized to the cellular exten-
sions, and thus might be involved in focal adhesion turn-
over, we visualized cellular localization of LAR as well as
that of the focal adhesion–associated cytoskeletal proteins
talin and vinculin, using immunofluorescence microscopy.
LAR was highly enriched along the length of the cellular
extensions, and was present in a punctate pattern (Fig. 8, a
and b). Talin and vinculin were also present in these exten-
sions, suggesting that focal adhesions are important for the
formation or functioning of these cellular extensions (Fig.
8, c and d). Talin and vinculin are also abundant in the cell
proper, where LAR was present in lower abundance. Pre-
dominant localization of LAR to the extended cell process
suggests a specific role for LAR in this location. Antibody-
induced internalization of LAR might inhibit formation of
the cellular extensions by affecting the assembly–disas-
sembly cycle of focal adhesion sites.
Figure 6. LAR cross-linking induces internalization of cell sur-
face LAR. HeLa cells were plated on a laminin–nidogen sub-
strate for 1 h (a), followed by LAR cross-linking with the anti-
LAR mAb 75.3A (b and c) as described in the legend to Fig. 5.
The cell surface LAR detected before LAR cross-linking (a) is
almost abolished after antibody-induced LAR cross-linking (b).
LAR staining of LAR cross-linked cells that have been perme-
abilized with 0.4% Triton X-100 reveal high concentrations of ag-
gregated internalized LAR (c). Cells were fixed with 3.7%
paraformaldehyde. LAR was stained with the anti-LAR mAb
11.1A and visualized by secondary staining with a TRITC-labeled
anti-mouse antibody.
Figure 7. LAR cross-linking inhibits laminin-induced cytoskele-
tal reorganization in HeLa cells. HeLa cells were plated on a
laminin–nidogen substrate, and LAR was cross-linked with the
anti-LAR mAb 75.3A as described in the legend to Fig. 5. Cells
were fixed with 3.7% paraformaldehyde, permeabilized with
0.4% Triton X-100, and stained for actin with rhodamine phalloi-
din. After initial cell attachment (1 h at 378C), the actin cytoskel-
eton displays a meshwork structure (a). 45 min later, a linear ac-
tin spike is seen extended into the cellular process of control
spreading cells (b). This actin spike is not observed in the LAR
cross-linked cells (c and d).The Journal of Cell Biology, Volume 141, 1998 1682
Discussion
Elucidation of ligands for the extracellular domain of
transmembrane PTPases is essential to understanding
their physiological role in regulating signal transduction.
Using GST fusion proteins representing LAR-FnIII do-
mains in binding assays, we have shown that the ECM
laminin–nidogen complex is a ligand for the LAR extra-
cellular domain. The laminin–nidogen binding site was
mapped to the LAR FnIII domain 5, and binding is regu-
lated by alternative splicing of a small exon within this do-
main. We have further shown that LAR may play a role in
regulating laminin–nidogen–induced cytoskeletal reorga-
nization during cell spreading.
The extracellular domain of LAR is composed of a com-
bination of Ig and FnIII domains similar to a number of
cell adhesion molecules such as the N-CAM family. Two
of these CAM-like molecules—NgCAM and the Deleted-
in-Colorectal-Cancer protein—have been reported to bind
laminin or a laminin-related protein netrin (10, 14). How-
ever, the laminin-binding region of these molecules has
not been elucidated, and these molecules differ from LAR
in that their cytoplasmic domains have no known direct
signaling capabilities.
Based on the crystal structure of a FnIII domain of fi-
bronectin (20), the amino acids encoded by the alterna-
tively spliced exon 13 is in a surface-exposed loop region
between b-pleated sheets. This position, together with the
highly charged nature of the 9 amino acids encoded by
exon 13 (WRPEESEDY), provides a potential mechanism
for disrupting laminin–nidogen binding activity. Alternative
splicing of exon 13 within the Fn5 domain is a conserved
feature of the LAR family PTPases (25, 28). This result
suggests that the FnIII domain 5 may function as a lami-
nin–nidogen-binding site for all members of the LAR family.
We have previously shown that the FnIII domain 4, and
FnIII domains 6 and 7, are also alternatively spliced. How-
ever, no specific ligands were found in our assays for the
LAR-FnIII domains 6 and 7 or for the LAR-FnIII domain
4. It is possible that splicing of these FnIII domains func-
tions in fine tuning the laminin–nidogen-binding proper-
ties of the FnIII domain 5. The lower laminin–nidogen-bind-
ing capacity of construct #8, in which Fn5 is directly linked
to Fn8 without the intervening Fn6 and Fn7, lends support
to this possibility (Fig. 2). Modulation of ligand binding of
the RGD sequence of fibronectin by alternative splicing of a
neighboring FnIII domain has been reported (22).
The relatively high level of expression of the non-lami-
nin–nidogen binding LAR Fn51 isoform in cells of neu-
ronal origin, and upregulation of the LAR-Fn51 isoform
in confluent fibroblasts (25, 42) suggest that the LAR ex-
tracellular domain may have other ligands. Such ligand-
binding activity may be mediated by the FnIII domains 1–3
or by the NH2-terminal Ig domains of LAR. Ig domains of
other cell surface proteins are often involved in ho-
mophilic and heterophilic interactions (29).
The LAR-Fn52 isoform is the predominant LAR iso-
form in most other cell types. Localization of both lami-
nin–nidogen and LAR at focal adhesion sites is consistent
with a role for the laminin–nidogen complex as an LAR
ligand. However, assessment of the laminin–nidogen-bind-
ing capacity of cell surface–expressed LAR is complicated
by coexpression of other laminin-binding cell surface mol-
ecules such as integrins, heparin sulfate, and b-1,4 galacto-
syltransferase (3, 27). Nevertheless, a role for LAR in
modulating laminin-nidogen-induced cell morphological
changes is indicated by the LAR antibody crosslinking
studies (Fig. 5). The mechanism by which LAR cross-link-
ing inhibits laminin–nidogen-induced cell spreading may
be twofold. The first possibility is that laminin–nidogen-
LAR binding and subsequent signaling is inhibited by an-
tibody-mediated downregulation of LAR from the cell
surface. LAR cross-linking does induce internalization of
LAR over the time period used in our studies (31; Fig. 6).
A second possibility is that antibody-induced LAR clus-
tering may interfere with laminin–nidogen-induced LAR
cellular localization, or may directly influence LAR PTP-
ase activity, generating a signal antagonistic to laminin–
nidogen-induced cell signaling. At the present time, our
data cannot distinguish between these possible effects of
LAR antibody cross-linking. Localization of both vinculin
and talin to the cellular extensions, and high enrichment of
LAR in these extensions (Fig. 8) suggest a role for LAR in
modulating the assembly/disassembly of focal adhesion
sites in these cellular extensions. This role for LAR would
be consistent with the previous localization of LAR to the
disassembly side of focal adhesions (31).
A crucial factor for regulating laminin-induced cell spread-
ing is modulation of cell signaling through tyrosine phos-
phorylation (2). Definition of the role of the LAR PTPase
activity requires elucidation of the physiological LAR sub-
strate(s) as well as determination of the effect of laminin–
nidogen–LAR binding on LAR PTPase activity. Few
physiological substrates have been identified for any of the
transmembrane PTPases. A number of potential LAR
substrates, the tyrosine phosphorylation of which are im-
plicated in cell spreading, are generated by laminin–
Figure 8. Indirect immunofluorescent staining of LAR (a and b),
and the focal adhesion components talin (c) and vinculin (d) in
HeLa cells spreading on a laminin–nidogen substrate. HeLa cells
were plated on laminin for 1 h and 45 min as described in the leg-
ends to Fig. 5. Cells were fixed and stained for cell surface LAR
with the anti-LAR mAb 11.1A as described in Fig. 6. Talin and
vinculin were stained in cells that were permeabilized with 0.4%
Triton X-100 after fixation. Stained proteins were visualized by
secondary staining with a TRITC-labeled anti-mouse antibody.O’Grady et al. Laminin Complex Binds Transmembrane PTPase LAR 1683
integrin interaction. These include the tyrosine kinases in-
volved in reorganization of the actin cytoskeleton, signaling
tyrosine kinases (FAK and Src), their downstream sub-
strates such as the signaling molecule p130 CAS, and the
cytoskeletal molecules tensin and paxillin (41).
There are a number of potential mechanisms (which are
not mutually exclusive) by which laminin–nidogen binding
to LAR may regulate LAR function. First, laminin–
nidogen binding could induce clustering of LAR. Laminin-
induced clustering of other cell surface ligands such as in-
tegrins, agrin, dystroglycan, and acetylcholine receptors
has been well-documented, and integrin clustering is es-
sential for FAK tyrosine kinase activation (4, 16, 38). Sec-
ond, laminin–nidogen–LAR binding could change cellular
localization of LAR, thus bringing it into the vicinity of its
physiological substrates. Localization of other cell surface
molecules is influenced by laminin binding (7, 23). The
high enrichment of LAR and its punctate expression ob-
served in the cellular processes formed by HeLa cells on a
laminin–nidogen substrate is suggestive of this type of
laminin-induced effect (Fig. 7). Third, since laminin–nidogen
is a large molecular complex capable of simultaneously
binding a number of ligands, laminin may cocluster LAR
with other laminin ligands. Fourth, laminin–LAR binding
may directly affect the LAR PTPase activity. At present,
we cannot distinguish among these possibilities. Nonethe-
less, binding of laminin to a specific splice isoform of LAR
may be the basis of a number of physiologically important
events in which LAR (or LAR-family phosphatases) has
been implicated, including cell migration, neuronal out-
growth, and mammary gland development (17, 30, 31).
The role of LAR in laminin-induced cell morphological
changes thus provides a focus for future studies to under-
stand the mechanism by which the LAR PTPase coordi-
nates laminin-induced cell signaling.
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